key: cord-0740869-ksq57yfw
authors: Tenbusch, Matthias; Schumacher, Sofie; Vogel, Emanuel; Priller, Alina; Held, Jürgen; Steininger, Philipp; Beileke, Stephanie; Irrgang, Pascal; Brockhoff, Ronja; Salmanton-García, Jon; Tinnefeld, Kathrin; Mijocevic, Hrvoje; Schober, Kilian; Bogdan, Christian; Yazici, Sarah; Knolle, Percy; Cornely, Oliver A; Überla, Klaus; Protzer, Ulrike
title: Heterologous prime–boost vaccination with ChAdOx1 nCoV-19 and BNT162b2
date: 2021-07-29
journal: Lancet Infect Dis
DOI: 10.1016/s1473-3099(21)00420-5
sha: 2e0a5951b12a6c3e8a3349b824cb36ca633e95ec
doc_id: 740869
cord_uid: ksq57yfw

nan

Supplementary Table S2 : Characteristics of cohorts analyzed in laboratory 2 (Erlangen, Germany)

Characteristics of cohorts analyzed in laboratory 2 (Erlangen, Germany) 5. Supplementary Figure S1 : Correlation of the surrogate neutralizing antibody assay and a cell-culture based infection inhibition assay using SARS-CoV-2 wild-type 6 

To evaluate standard mRNA vaccination, employees of the University Hospital rechts der Table S1 . 

Healthcare workers were offered analysis of their neutralizing antibody responses to SARS-CoV-2 two to three weeks after the second BNT162b2 mRNA vaccination. Given the uncertain immunogenicity of heterologous prime boost vaccinations, recipients of a priming vaccination with ChAdOx1 nCoV-19, who had received a second vaccination with ChAdOx1 nCoV-19 or BNT162b2 mRNA on April 29 th , 2021, at the public vaccination center in Erlangen were offered to register by phone for blood sampling appointments 14 to 16 days after the second vaccination. Blood samples and information on age, sex, and dates of first and second vaccination were obtained from 316 volunteers (for Summary see Table S2 ).

Volunteers reporting prior SARS-CoV-2 infection were excluded. The surrogate neutralization assay, in contrast, was done with undiluted serum and therefore allowed a quantification also when serum neutralization activity was low. 

Ethics Statement The retrospective analysis plan on the comparison of the SARS-CoV-2 antibody levels in response to different vaccine regimens was approved by the local ethics committees in Erlangen (Az. 202_21 Bc) and Munich

Funding Statement Funded by the German Centre for Infection Research (DZIF), the European Union's "Horizon 2020 Research and Innovation Programme" under grant agreement

Bayerisches Staatsministerium für Wissenschaft und Kunst" for the CoVaKo-2021 and the For-COVID projects and the Helmholtz Association via the collaborative research program "CoViPa". Further support was obtained from the Federal Ministry of Education and Science (BMBF) through the "Netzwerk Universitätsmedizin

Kirsten Fraedrich for and Norbert Donhauser, excellent technical assistance. We are grateful to Martina Rupp, Oana Wehrmann and Nives Schwerdtner for their help in arranging the appointments for the vaccinees and setting up the blood sampling site at the Microbiology Institute in Erlangen and to all medical doctoral students for their assistance